TOXICOLOGICAL PROFILE FOR
CHLORINATED DIBENZO-\(p\)-DIOXINS

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

December 1998
DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.
UPDATE STATEMENT

A toxicological profile for chlorinated dibenzo-p-dioxins was released in February 1998. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protect public health will be identified by ATSDR and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

Each profile must include the following:

(A) An examination, summary, and interpretation of available toxicological information and epidemiological evaluations on the hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.

(C) Where appropriate, identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The availability of the revised priority list of the 275 hazardous substances was announced in the Federal Register on February 28, 1994 (59 FR 9486). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); and October 28, 1992 (57 FR 48801).
Section 104 (i) (3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Jeffrey P. Koplan, M.D., M.P.H.
Administrator
Agency for Toxic Substances and Disease Registry
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

**Primary Chapters/Sections of Interest**

**Chapter 1: Public Health Statement**: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

**Chapter 2: Health Effects**: Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

*NOTE*: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

**Pediatrics**: Four new sections have been added to each Toxicological Profile to address child health issues:

- **Section 1.6** How Can (Chemical X) Affect Children?
- **Section 1.7** How Can Families Reduce the Risk of Exposure to (Chemical X)?
- **Section 2.6** Children’s Susceptibility
- **Section 5.6** Exposures of Children

**Other Sections of Interest**:

- **Section 2.7** Biomarkers of Exposure and Effect
- **Section 2.10** Methods for Reducing Toxic Effects

**ATSDR Information Center**

- **Phone**: 1-800-447-1544 (to be replaced by 1-888-42-ATSDR in 1999)
- **Fax**: 404-639-6359
- **E-mail**: atsdric@cdc.gov
- **Internet**: http://atsdr1.atsdr.cdc.gov:8080

The following additional material can be ordered through the ATSDR Information Center:

**Case Studies in Environmental Medicine: Taking an Exposure History**—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure
history is provided. Other case studies of interest include *Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

*Managing Hazardous Materials Incidents* is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

*Fact Sheets (ToxFaqs)* provide answers to frequently asked questions about toxic substances.

---

**Other Agencies and Organizations**

*The National Center for Environmental Health* (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. **Contact:** NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

*The National Institute for Occupational Safety and Health* (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. **Contact:** NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

*The National Institute of Environmental Health Sciences* (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. **Contact:** NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

---

**Referrals**

*The Association of Occupational and Environmental Clinics* (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. **Contact:** AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: aoec@dgs.dgsys.com • AOEC Clinic Director: [http://oec-env-med.mc.duke.edu/oem/aoec.htm](http://oec-env-med.mc.duke.edu/oem/aoec.htm).

*The American College of Occupational and Environmental Medicine* (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. **Contact:** ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Hana Pohl, M.D., Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Fernando Llados, Ph.D.
Research Triangle Institute, Research Triangle Park, NC

Lisa Ingerman, Ph.D.
Syracuse Research Corporation, Syracuse, NY

Patricia Cunningham, Ph.D.
Research Triangle Institute, Research Triangle Park, NC

James H. Raymer, Ph.D.
Research Triangle Institute, Research Triangle Park, NC

Constance Wall, B.S.
Research Triangle Institute, Research Triangle Park, NC

Thomas Gasiewicz, Ph.D.
University of Rochester Medical Center, Rochester, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

2. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
A peer review panel was assembled for chlorinated dibenzo-

\[ \textit{p} \text{-dioxins}. \] The panel consisted of the following members:

1. James Olson, Department of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, NY;
2. John Ryan, Bureau of Chemical Safety, Health and Welfare Canada, Ottawa, Ontario, Canada; and
3. Arnold Schecter, College of Medicine, State University of New York, Health Science Center, Binghamton, NY.

These experts collectively have knowledge of chlorinated dibenzo-

\[ \textit{p} \text{-dioxins}' physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.
PAST PEER-REVIEWS

Several drafts of the Toxicological Profile for Chlorinated Dibenzo-p-Dioxins were submitted for a peer-review in the past.

**Draft 1997**

- **Ross Norstrom**, National Wildlife Research Center, Environment Canada, Hull, Quebec, Canada
- **James Olson**, Department of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, NY
- **Dennis Paustenbach**, McLaren/Hart ChemRisk, Alameda, CA
- **John Ryan**, Bureau of Chemical Safety, Health and Welfare Canada, Ottawa, Ontario, Canada
- **Arnold Schecter**, College of Medicine, State University of New York, Health Science Center, Binghamton, NY

**Draft 1994 (scientific panel meeting)**

- **Anthony DeCaprio**, Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany, NY
- **Thomas Gasiewicz**, University of Rochester Medical Center, Rochester, NY
- **Ross Norstrom**, National Wildlife Research Center, Environment Canada, Hull, Quebec, Canada
- **James Olson**, Department of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, NY
- **Dennis Paustenbach**, McLaren/Hart ChemRisk, Alameda, CA
- **John Ryan**, Bureau of Chemical Safety, Health and Welfare Canada, Ottawa, Ontario, Canada
- **Arnold Schecter**, College of Medicine, State University of New York, Health Science Center, Binghamton, NY

**Draft 1992**

- **Thomas Gasiewicz**, University of Rochester Medical Center, Rochester, NY
- **James Olson**, Department of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, NY
- **Arnold Schecter**, College of Medicine, State University of New York, Health Science Center, Binghamton, NY

**Draft 1991**

- **Thomas Gasiewicz**, University of Rochester Medical Center, Rochester, NY
- **Arleen Rifkind**, Cornell University of Medical College, New York, NY
- **Arnold Schecter**, College of Medicine, State University of New York, Health Science Center, Binghamton, NY
- **Jay Silkworth**, Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany, NY
# CONTENTS

**FOREWORD** ......................................................................................... v

**QUICK REFERENCE FOR HEALTH CARE PROVIDERS** .............................. vii

**CONTRIBUTORS** ............................................................................. ix

**PEER REVIEW** ................................................................................. xi

**LIST OF FIGURES** ........................................................................... xvii

**LIST OF TABLES** .............................................................................. xix

1. **PUBLIC HEALTH STATEMENT** ................................................................. 1
   1.1 WHAT ARE CDDS? ............................................................................... 1
   1.2 WHAT HAPPENS TO CDDS WHEN THEY ENTER THE ENVIRONMENT? .... 3
   1.3 HOW MIGHT I BE EXPOSED TO CDDS? ........................................ 5
   1.4 HOW CAN CDDS ENTER AND LEAVE MY BODY? .................. 8
   1.5 HOW CAN CDDS AFFECT MY HEALTH? ..................................... 9
   1.6 HOW CAN CDDs AFFECT CHILDREN? ........................................ 13
   1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO CDDs? .... 14
   1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO CDDs? ................................................................. 15
   1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? ......................................................... 16
   1.10 WHERE CAN I GET MORE INFORMATION? .................................. 17

2. **HEALTH EFFECTS** ............................................................................ 19
   2.1 HUMAN STUDIES ........................................................................... 19
      2.1.1 Death ....................................................................................... 26
      2.1.2 Systemic Effects ......................................................................... 27
      2.1.3 Immunological Effects .............................................................. 42
      2.1.4 Neurological Effects ................................................................... 46
      2.1.5 Reproductive Effects .................................................................. 49
      2.1.6 Developmental Effects ............................................................... 52
      2.1.7 Genotoxic Effects ...................................................................... 55
      2.1.8 Cancer ....................................................................................... 56
   2.2. ANIMAL STUDIES ......................................................................... 68
      2.2.1 Inhalation Exposure ................................................................. 69
         2.2.1.1 Death .................................................................................... 69
         2.2.1.2 Systemic Effects ................................................................... 69
         2.2.1.3 Immunological Effects ........................................................... 69
         2.2.1.4 Neurological Effects ............................................................... 69
         2.2.1.5 Reproductive Effects ............................................................... 69
         2.2.1.6 Developmental Effects ............................................................. 69
         2.2.1.7 Genotoxic Effects .................................................................. 69
         2.2.1.8 Cancer ................................................................................... 69
      2.2.2 Oral Exposure ............................................................................. 69
         2.2.2.1 Death .................................................................................... 70
2.11 ADEQUACY OF THE DATABASE .................................................. 330
  2.11.1 Existing Information on Health Effects of CDDs ........................ 330
  2.11.2 Identification of Data Needs ............................................ 333
  2.11.4 Ongoing Studies .......................................................... 345

3. CHEMICAL AND PHYSICAL INFORMATION ....................................... 357
  3.1 CHEMICAL IDENTITY ................................................................ 357
  3.2 PHYSICAL AND CHEMICAL PROPERTIES .................................... 357

4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL ............................ 369
  4.1 PRODUCTION ........................................................................ 369
  4.2 IMPORT/EXPORT ................................................................. 371
  4.3 USE ................................................................................... 371
  4.4 DISPOSAL ............................................................................ 371

5. POTENTIAL FOR HUMAN EXPOSURE .............................................. 377
  5.1 OVERVIEW ............................................................................ 377
  5.2 RELEASES TO THE ENVIRONMENT .......................................... 382
    5.2.1 Air ............................................................................... 390
    5.2.2 Water ............................................................................ 396
    5.2.3 Soil ............................................................................... 399
  5.3 ENVIRONMENTAL FATE ......................................................... 400
    5.3.1 Transport and Partitioning ................................................ 401
    5.3.2 Transformation and Degradation ........................................ 419
      5.3.2.1 Air ......................................................................... 419
      5.3.2.2 Water ....................................................................... 420
      5.3.2.3 Sediment and Soil .................................................... 423
  5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .......... 426
    5.4.1 Air ............................................................................... 426
    5.4.2 Water ............................................................................ 431
    5.4.3 Sediment and Soil .......................................................... 434
    5.4.4 Other Environmental Media ............................................. 442
  5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE .......... 461
    5.5.1 General Population .......................................................... 461
    5.5.2 Occupational Exposure ................................................... 474
  5.6 EXPOSURES OF CHILDREN ...................................................... 477
  5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES ............... 485
  5.8 ADEQUACY OF THE DATABASE ............................................... 497
    5.8.1 Identification of Data Needs ............................................. 498
    5.8.2 Ongoing Studies ............................................................ 502

6. ANALYTICAL METHODS .............................................................. 507
  6.1 BIOLOGICAL SAMPLES .......................................................... 507
  6.2 ENVIRONMENTAL SAMPLES ................................................... 522
  6.3 ADEQUACY OF THE DATABASE ............................................... 525
    6.3.1 Identification of Data Needs ............................................. 526
    6.3.2 Ongoing Studies ............................................................ 527

7. REGULATIONS AND ADVISORIES .................................................. 529
8. REFERENCES ................................................................. 543
9. GLOSSARY ................................................................. 673

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS ................. A-1
B. ATSDR POLICY GUIDELINE (Updated September 2008).................... B-1
C. USER'S GUIDE........................................................................... C-1
D. ACRONYMS, ABBREVIATIONS, AND SYMBOLS ......................... D-1
# LIST OF FIGURES

2-1 Levels of Significant Exposure to 2,3,7,8-TCDDs - Oral ........................................ 118

2-2 Levels of Significant Exposure to Dioxins (non-2,3,7,8-TCDD) - Oral ....................... 141

2-3 A Generalized Scheme of Pathways for the Biotransformation of CDDs Based on Information from *In Vivo* Mammalian Studies ........................................ 199

2-4 Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance .................................................. 212

2-5 Existing Information on Health Effects of 2,3,7,8-TCDD ........................................ 331

2-6 Existing Information on Health Effects of Other CDDs ......................................... 332

5-1 Frequency of NPL Sites with 2,3,7,8-TCDD Contamination ....................................... 383

5-2 Frequency of NPL Sites with Total Dioxin Contamination ....................................... 384

5-3 Frequency of NPL Sites with Tetra Dioxins Contamination .................................... 385

5-4 Frequency of NPL Sites with Penta Dioxins Contamination .................................... 386

5-5 Frequency of NPL Sites with Hexa Dioxins Contamination .................................... 387

5-6 Frequency of NPL Sites with Hepta Dioxins Contamination .................................... 388

5-7 Frequency of NPL Sites with Octa Dioxins Contamination .................................... 389

5-8 National Listing of Fish and Wildlife Consumption Advisories for Dioxins ................. 486
LIST OF TABLES

2-1 Health Effects in Humans Associated with Estimated 2,3,7,8-TCDD Body Burdens ........... 21
2-2 Levels of Significant Exposure to 2,3,7,8-TCDD - Oral ......................................... 74
2-3 Levels of Significant Exposure to Dioxins (non-2,3,7,8-TCDD) - Oral ......................... 127
2-4 Levels of Significant Exposure to 2,3,7,8-TCDD - Dermal ...................................... 179
2-5 Levels of Significant Exposure to Dioxins (non-2,3,7,8-TCDD) - Dermal ................... 184
2-6 Mean Levels of CDDs in Breast Milk ................................................................. 204
2-7 Pharmacokinetic Parameters of 2,3,7,8-TCDD Used in PBPK Models ....................... 216
2-8 Comparison of Health Effects Among Species Exposed to CDDs ............................. 248
2-9 Comparison of LOAELs Among Animal Species Following a Single Oral Dose of 2,3,7,8-TCDD ................................................................. 249
2-10 Comparison of Body Burden Effects Levels Among Humans and Animals ................ 251
2-11 Toxicity Equivalency Factors (TEFs) for Halogenated Aromatic Hydrocarbons ......... 257
2-12 World Health Organization TEFs for Humans, Mammals, Fish, and Birds .......... 258
2-13 Estimated Body Burdens of 2,3,7,8-TCDD That Correspond to MRLs ...................... 267
2-14 Health Effects in Animals Following Lactation-Only Exposure to 2,3,7,8-TCDD ........... 301
2-15 Health Effects in Humans Associated with CDD and CDF Levels in Breast Milk .......... 302
2-16 Genotoxicity of 2,3,7,8-TCDD In Vivo ............................................................... 305
2-17 Genotoxicity of 2,3,7,8-TCDD In Vitro ............................................................... 308
2-18 Ongoing Studies on CDDs ................................................................................. 346
3-1 Chemical Identity of CDDs .................................................................................. 358
3-2 Physical and Chemical Properties of CDDs ......................................................... 362
5-1 Number of NPL Sites Where CDDs Have Been Detected in One or More Environmental Media ................................................................. 397
5-2 Rain Scavenging Ratios (RS) and Percent Washout Due to Particulates (%W) for CDDs and CDFs in Ambient Air in Two Midwest Cities ................................................. 402
5-3 Bioconcentration Factors (BCFs) for Aquatic Organisms ...................................... 408